Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05839041 · ClinicalTrials.gov registry record · Phase 2
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Phase 2 study of Macular Degeneration and Geographic Atrophy of the Macula, sponsored by Aviceda Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05839041: Active Phase 2 study of Macular Degeneration and Geographic Atrophy of the Macula, sponsored by Aviceda Therapeutics.
NCT05839041 is a Phase 2 study of Macular Degeneration and Geographic Atrophy of the Macula that is active but no longer recruiting, run by Aviceda Therapeutics. The registered enrollment target is 300 participants, above the 168-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05839041, a Phase 2 study of Macular Degeneration and Geographic Atrophy of the Macula, is active but no longer recruiting, sponsored by Aviceda Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Primary Outcome
The number of participants experiencing a dose limiting toxicity corresponding to a category of 3 or greater on the National Cancer Institute Common Terminology Criteria for Adverse Events
Conditions Studied
Interventions
- DRUG AVD-104
- DRUG Avacincaptad
Study Locations (20)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Macula & Retina Institute - Glendale
- Northern California Retina Vitreous Associates - Mountain View
- Kaiser Permanente - Riverside
- Retinal Consultants Medical Group, Inc. - Sacramento
- Retinal Consultants Medical Group - Sacramento
- West Coast Retina - San Francisco
- RCA: California Retina Consultants - Santa Barbara
Florida
- Rand Eye Institute - Deerfield Beach
- Retina Group of Florida - Fort Lauderdale
- Florida Retina Institute - Orlando
- Retina Specialty Institute - Pensacola
- Retina Vitreous Associates of Florida - St. Petersburg
- Southern Vitreoretinal Associates - Tallahassee
- Center for Retina & Macular Disease - Winter Haven
Arizona
- Associated Retina Consultants - Gilbert
- Arizona Retina and Vitreous Consultants - Phoenix
- Associated Retina Consultants - Scottsdale
Connecticut
- Retina Group of New England, PC - Waterford
Georgia
- Southeast Retina Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-05-02 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT05839041 still lists
NCT05839041 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 168-participant average among 26 other Macular Degeneration trials with a reported enrollment target (79% higher).
The record links to 2 conditions, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which AVD-104 is the first listed.
NCT05839041 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05839041 about?
NCT05839041 is a clinical study titled "A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)". Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
What is the current status of trial NCT05839041?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2023-05-02. Estimated completion is 2026-10.
What conditions does trial NCT05839041 study?
This clinical trial studies the following conditions: Macular Degeneration, Geographic Atrophy of the Macula.
What interventions are being tested in trial NCT05839041?
The interventions under investigation include: AVD-104 (DRUG), Avacincaptad (DRUG).
Who is sponsoring clinical trial NCT05839041?
This trial is sponsored by Aviceda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05839041 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05839041's enrollment target sits among peer trials
300 3rd of 26 higher than 24 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 2
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI